Mirimus, Inc.

Mirimus, Inc. is a biotech company that focuses on preclinical evaluation of therapeutic targets using advanced genetically engineered models, providing innovative solutions for drug discovery and validation. Founded in 2010 and headquartered in Brooklyn, US, Mirimus, Inc. specializes in preclinical evaluation using custom RNA interference (RNAi) and CRISPR/Cas9 models.

The company raised USD 2. 00 mn in Series A funding in March 2011 from Delphi Ventures and Topspin Partners, bringing its total amount raised to USD 2. 00 mn and its current valuation to USD 6. 868 mn.

Mirimus specializes in innovative biotech solutions, focusing on preclinical evaluation through advanced genetically engineered in vivo models. The company's core offerings include custom RNA interference (RNAi) and CRISPR/Cas9 mouse and rat models for precise gene silencing in drug discovery. Furthermore, Mirimus develops 3D tissue cultures from induced pluripotent stem cells (iPSCs), emulating human organ architecture and physiology. These products are utilized by researchers and pharmaceutical companies for in vivo studies in oncology, neurology, and cardiovascular diseases, serving clients primarily in North America, Europe, and Asia.

Mirimus generates revenue mainly through B2B transactions with pharmaceutical and biotech companies, academic institutions, and research organizations. The company offers structured partnerships and custom contracts tailored to specific research needs, including animal models and tissue cultures. Revenue is derived from service agreements reflecting the complexity and duration of projects, ensuring that products meet client specifications. This model fosters long-term relationships with clients, enhancing revenue potential and the impact of its offerings in drug discovery.

Mirimus aims to develop new products, including enhanced models and advanced tissue cultures, although specific release dates are not disclosed. The company is also looking to expand into European and Asian markets by 2015. The recent funding of USD 2. 00 mn raised in March 2011 will support these initiatives, facilitating research enhancements and market expansion.